Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Update

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 6,989 shares, a decrease of 60.8% from the April 15th total of 17,844 shares. Based on an average trading volume of 9,266 shares, the days-to-cover ratio is currently 0.8 days. Approximately 0.0% of the shares of the stock are short sold.

Spectral Diagnostics Stock Down 1.9%

OTCMKTS:EDTXF traded down $0.02 during mid-day trading on Friday, reaching $1.02. 200 shares of the company were exchanged, compared to its average volume of 9,697. Spectral Diagnostics has a 12 month low of $0.58 and a 12 month high of $1.31. The company has a fifty day moving average of $1.00 and a 200 day moving average of $0.99. The stock has a market cap of $299.29 million, a PE ratio of -10.20 and a beta of 0.09.

Spectral Diagnostics (OTCMKTS:EDTXF) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.